BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Gilead Sciences readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies Gilead Sciences's drugs run\, fro
 m ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT05299424-3157@assetmemo.bio
DTSTAMP:20261121T004512Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Gamgertamig (CM336): Phase 1/2 readout est. (NCT05299424)
DESCRIPTION:Gamgertamig (CM336)\, phase 1/2\, Multiple Myeloma.\nStudy: A S
 tudy of CM336 in Patients With Relapsed or Refractory Multiple Myeloma\nEs
 timated primary completion: December 2026. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/gamgertamig-cm336#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT05299424
URL:https://assetmemo.bio/drug/gamgertamig-cm336#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05396885-3142@assetmemo.bio
DTSTAMP:20261121T004512Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Anitocabtagene autoleucel: Phase 2 readout est. (NCT05396885)
DESCRIPTION:Anitocabtagene autoleucel\, phase 2\, Multiple Myeloma.\nStudy:
  Study of Anitocabtagene-autoleucel in Relapsed or Refractory Multiple Mye
 loma (iMMagine-1)\nEstimated primary completion: December 2026. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/anitocabtagene-autoleucel#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT05396885
URL:https://assetmemo.bio/drug/anitocabtagene-autoleucel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04639986-1992@assetmemo.bio
DTSTAMP:20261121T004512Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Sacituzumab Govitecan: Phase 3 readout est. (NCT04639986)
DESCRIPTION:Sacituzumab Govitecan\, phase 3\, HR+/HER2- Metastatic Breast C
 ancer.\nStudy: Asian Study of Sacituzumab Govitecan (IMMU-132) in HR+/HER2
 - Metastatic Breast Cancer (MBC)\nEstimated primary completion: December 2
 026. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/sacituzumab-govi
 tecan#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT04639986
URL:https://assetmemo.bio/drug/sacituzumab-govitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05382286-1992@assetmemo.bio
DTSTAMP:20261121T004512Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:Sacituzumab Govitecan: Phase 3 readout est. (NCT05382286)
DESCRIPTION:Sacituzumab Govitecan\, phase 3\, Breast Cancer.\nStudy: Study 
 of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physic
 ian's Choice and Pembrolizumab in Patients With Previously Untreated\, Loc
 ally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer\nEsti
 mated primary completion: February 2027. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/sacituzumab-govitecan#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT05382286
URL:https://assetmemo.bio/drug/sacituzumab-govitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05186974-1992@assetmemo.bio
DTSTAMP:20261121T004512Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Sacituzumab Govitecan: Phase 2 readout est. (NCT05186974)
DESCRIPTION:Sacituzumab Govitecan\, phase 2\, Non-Small Cell Lung Cancer.\n
 Study: Study of Sacituzumab Govitecan Combinations in First-line Treatment
  of Participants With Advanced or Metastatic Non-Small-Cell Lung Cancer (N
 SCLC)\nEstimated primary completion: March 2027. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/sacituzumab-govitecan#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT05186974
URL:https://assetmemo.bio/drug/sacituzumab-govitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06749054-966@assetmemo.bio
DTSTAMP:20261121T004512Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Lenacapavir (Sunlenca): Phase 2 readout est. (NCT06749054)
DESCRIPTION:Lenacapavir (Sunlenca)\, phase 2\, HIV.\nStudy: Evaluation of L
 ong-Acting Lenacapavir for the Treatment of HIV-1 in Treatment-experienced
  Adolescents and Children\nEstimated primary completion: March 2027. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/lenacapavir-sunlenca#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT06749054
URL:https://assetmemo.bio/drug/lenacapavir-sunlenca#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05101096-1992@assetmemo.bio
DTSTAMP:20261121T004512Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Sacituzumab Govitecan: Phase 1/2 readout est. (NCT05101096)
DESCRIPTION:Sacituzumab Govitecan\, phase 1/2\, HR+/HER2- Metastatic Breast
  Cancer.\nStudy: Study of Sacituzumab Govitecan (SG) in Japanese Participa
 nts With Advanced Solid Tumors\nEstimated primary completion: May 2027. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/sacituzumab-govitecan#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT05101
 096
URL:https://assetmemo.bio/drug/sacituzumab-govitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07554495-16@assetmemo.bio
DTSTAMP:20261121T004512Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Jyseleca (filgotinib): Phase 3 readout est. (NCT07554495)
DESCRIPTION:Jyseleca (filgotinib)\, phase 3.\nStudy: Safety\, Tolerability\
 , Pharmacokinetics\, and Efficacy of Filgotinib for the Treatment of Polya
 rticular-course Juvenile Idiopathic Arthritis in Children and Adolescents\
 nEstimated primary completion: June 2027. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/filgotinib#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT07554495
URL:https://assetmemo.bio/drug/filgotinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05633654-1992@assetmemo.bio
DTSTAMP:20261121T004512Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Sacituzumab Govitecan: Phase 3 readout est. (NCT05633654)
DESCRIPTION:Sacituzumab Govitecan\, phase 3\, Breast Cancer.\nStudy: Study 
 of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physic
 ian's Choice in Patients With Triple Negative Breast Cancer Who Have Resid
 ual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-
 65 OptimICE-RD/GBG 119/NSABP B-63)\nEstimated primary completion: June 202
 7. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, 
 and it can move.\nDrug page: https://assetmemo.bio/drug/sacituzumab-govite
 can#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 05633654
URL:https://assetmemo.bio/drug/sacituzumab-govitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07645287-966@assetmemo.bio
DTSTAMP:20261121T004512Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Lenacapavir (Sunlenca): Phase 2 readout est. (NCT07645287)
DESCRIPTION:Lenacapavir (Sunlenca)\, phase 2\, HIV.\nStudy: A Study of GS-3
 242 in Combination With Lenacapavir Versus Biktarvy in Virologically Suppr
 essed People With HIV-1\nEstimated primary completion: August 2027. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/lenacapavir-sunlenca#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT07645287
URL:https://assetmemo.bio/drug/lenacapavir-sunlenca#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07841990-966@assetmemo.bio
DTSTAMP:20261121T004512Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Lenacapavir (Sunlenca): Phase 2 readout est. (NCT07841990)
DESCRIPTION:Lenacapavir (Sunlenca)\, phase 2\, HIV.\nStudy: Substudy-01: A 
 Study of Long-Acting HIV-1 Treatments Taken by Mouth in People With HIV-1 
 With Undetectable Virus Levels\nEstimated primary completion: August 2027.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/lenacapavir-sunlenca
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT078
 41990
URL:https://assetmemo.bio/drug/lenacapavir-sunlenca#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07181239-3157@assetmemo.bio
DTSTAMP:20261121T004512Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Gamgertamig (CM336): Phase 3 readout est. (NCT07181239)
DESCRIPTION:Gamgertamig (CM336)\, phase 3\, Multiple Myeloma.\nStudy: Study
  of CM336 in Relapsed or Refractory Multiple Myeloma Patients\nEstimated p
 rimary completion: September 2027. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/gamgertamig-cm336#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT07181239
URL:https://assetmemo.bio/drug/gamgertamig-cm336#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07175493-3157@assetmemo.bio
DTSTAMP:20261121T004512Z
DTSTART;VALUE=DATE:20271118
DTEND;VALUE=DATE:20271119
SUMMARY:Gamgertamig (CM336): Phase 1/2 readout est. (NCT07175493)
DESCRIPTION:Gamgertamig (CM336)\, phase 1/2.\nStudy: A Study of CM336 in Pa
 tients With Relapsed or Refractory Autoimmune Cytopenia\nEstimated primary
  completion: 18 November 2027. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/gamgertamig-cm336#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT07175493
URL:https://assetmemo.bio/drug/gamgertamig-cm336#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06303505-2785@assetmemo.bio
DTSTAMP:20261121T004512Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:TUB-040: Phase 1/2 readout est. (NCT06303505)
DESCRIPTION:TUB-040\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: FiH S
 tudy to Investigate Safety\, PK and Efficacy of the NaPi2b ADC TUB-040 in 
 Patients With PROC or r/r Adenocarcinoma NSCLC\nEstimated primary completi
 on: December 2027. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/tu
 b-040#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT06303505
URL:https://assetmemo.bio/drug/tub-040#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05676931-2695@assetmemo.bio
DTSTAMP:20261121T004512Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Quemliclustat: Phase 2 readout est. (NCT05676931)
DESCRIPTION:Quemliclustat\, phase 2.\nStudy: Study With Various Immunothera
 py Treatments in Participants With Lung Cancer\nEstimated primary completi
 on: December 2027. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/qu
 emliclustat#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT05676931
URL:https://assetmemo.bio/drug/quemliclustat#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07553182-16@assetmemo.bio
DTSTAMP:20261121T004512Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Jyseleca (filgotinib): Phase 3 readout est. (NCT07553182)
DESCRIPTION:Jyseleca (filgotinib)\, phase 3.\nStudy: OLE Study With Filgoti
 nib in JIA\nEstimated primary completion: December 2027. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/filgotinib#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT07553182
URL:https://assetmemo.bio/drug/filgotinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07736937-2785@assetmemo.bio
DTSTAMP:20261121T004512Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:TUB-040: Phase 1/2 readout est. (NCT07736937)
DESCRIPTION:TUB-040\, phase 1/2\, Ovarian Cancer.\nStudy: Study of TUB-040 
 Given With Standard Ovarian Cancer Drugs in Patients With Fast-growing Ova
 rian Cancer\nEstimated primary completion: March 2028. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/tub-040#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT07736937
URL:https://assetmemo.bio/drug/tub-040#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05840211-1992@assetmemo.bio
DTSTAMP:20261121T004512Z
DTSTART;VALUE=DATE:20280430
DTEND;VALUE=DATE:20280501
SUMMARY:Sacituzumab Govitecan: Phase 3 readout est. (NCT05840211)
DESCRIPTION:Sacituzumab Govitecan\, phase 3\, HR+/HER2- Metastatic Breast C
 ancer.\nStudy: Study of Sacituzumab Govitecan Versus Treatment of Physicia
 n's Choice in Patients With Hormone Receptor-positive/Human Epidermal Grow
 th Factor Receptor 2 Negative (HR+/HER2-) Metastatic Breast Cancer Who Hav
 e Received Endocrine Therapy\nEstimated primary completion: April 2028. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/sacituzumab-govitecan#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT05840
 211
URL:https://assetmemo.bio/drug/sacituzumab-govitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06926920-1992@assetmemo.bio
DTSTAMP:20261121T004512Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Sacituzumab Govitecan: Phase 1/2 readout est. (NCT06926920)
DESCRIPTION:Sacituzumab Govitecan\, phase 1/2\, Breast Cancer.\nStudy: A St
 udy of Sacituzumab Govitecan Given at an Alternative Dose and Schedule in 
 Participants With Advanced Triple-Negative Breast Cancer\nEstimated primar
 y completion: June 2028. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/sacituzumab-govitecan#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT06926920
URL:https://assetmemo.bio/drug/sacituzumab-govitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06865417-16@assetmemo.bio
DTSTAMP:20261121T004512Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Jyseleca (filgotinib): Phase 3 readout est. (NCT06865417)
DESCRIPTION:Jyseleca (filgotinib)\, phase 3.\nStudy: A Study Evaluating the
  Effects of Filgotinib in Children and Teenagers With Ulcerative Colitis\n
 Estimated primary completion: June 2028. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/filgotinib#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT06865417
URL:https://assetmemo.bio/drug/filgotinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05382299-1992@assetmemo.bio
DTSTAMP:20261121T004512Z
DTSTART;VALUE=DATE:20280731
DTEND;VALUE=DATE:20280801
SUMMARY:Sacituzumab Govitecan: Phase 3 readout est. (NCT05382299)
DESCRIPTION:Sacituzumab Govitecan\, phase 3\, Breast Cancer.\nStudy: Study 
 of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Pa
 tients With Previously Untreated Locally Advanced Inoperable or Metastatic
  Triple-Negative Breast Cancer\nEstimated primary completion: July 2028. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/sacituzumab-govitecan#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0538
 2299
URL:https://assetmemo.bio/drug/sacituzumab-govitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06413498-3142@assetmemo.bio
DTSTAMP:20261121T004512Z
DTSTART;VALUE=DATE:20280731
DTEND;VALUE=DATE:20280801
SUMMARY:Anitocabtagene autoleucel: Phase 3 readout est. (NCT06413498)
DESCRIPTION:Anitocabtagene autoleucel\, phase 3\, Multiple Myeloma.\nStudy:
  A Study Comparing Anitocabtagene Autoleucel to Standard of Care Therapy i
 n Participants With Relapsed/ Refractory Multiple Myeloma\nEstimated prima
 ry completion: July 2028. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/anitocabtagene-autoleucel#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT06413498
URL:https://assetmemo.bio/drug/anitocabtagene-autoleucel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07047716-11049@assetmemo.bio
DTSTAMP:20261121T004512Z
DTSTART;VALUE=DATE:20280930
DTEND;VALUE=DATE:20281001
SUMMARY:Lenacapavir (Yeztugo): Phase 3 readout est. (NCT07047716)
DESCRIPTION:Lenacapavir (Yeztugo)\, phase 3\, HIV.\nStudy: Study of Lenacap
 avir as a Once-Yearly Injection for HIV Pre-exposure Prophylaxis (PrEP)\nE
 stimated primary completion: September 2028. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/lenacapavir-yeztugo#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT07047716
URL:https://assetmemo.bio/drug/lenacapavir-yeztugo#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03301506-1117@assetmemo.bio
DTSTAMP:20261121T004512Z
DTSTART;VALUE=DATE:20281130
DTEND;VALUE=DATE:20281201
SUMMARY:Livdelzi (Seladelpar): Phase 3 readout est. (NCT03301506)
DESCRIPTION:Livdelzi (Seladelpar)\, phase 3\, Primary Biliary Cholangitis.\
 nStudy: Study of Seladelpar in Participants With Primary Biliary Cholangit
 is (PBC)\nEstimated primary completion: November 2028. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/seladelpar#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT03301506
URL:https://assetmemo.bio/drug/seladelpar#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07841977-1117@assetmemo.bio
DTSTAMP:20261121T004512Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Livdelzi (Seladelpar): Phase 2 readout est. (NCT07841977)
DESCRIPTION:Livdelzi (Seladelpar)\, phase 2\, Primary Biliary Cholangitis.\
 nStudy: Study of Seladelpar and Cilofexor in Participants With Primary Bil
 iary Cholangitis\nEstimated primary completion: December 2028. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/seladelpar#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT07841977
URL:https://assetmemo.bio/drug/seladelpar#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07682961-966@assetmemo.bio
DTSTAMP:20261121T004512Z
DTSTART;VALUE=DATE:20290331
DTEND;VALUE=DATE:20290401
SUMMARY:Lenacapavir (Sunlenca): Phase 3 readout est. (NCT07682961)
DESCRIPTION:Lenacapavir (Sunlenca)\, phase 3\, HIV.\nStudy: Study of Lenaca
 pavir\, Teropavimab\, and Zinlirvimab Versus Cabotegravir and Rilpivirine 
 in Virologically Suppressed Adults With HIV-1 on Oral Daily Antiretroviral
  Therapy\nEstimated primary completion: March 2029. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/lenacapavir-sunlenca#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT07682961
URL:https://assetmemo.bio/drug/lenacapavir-sunlenca#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07683000-966@assetmemo.bio
DTSTAMP:20261121T004512Z
DTSTART;VALUE=DATE:20290331
DTEND;VALUE=DATE:20290401
SUMMARY:Lenacapavir (Sunlenca): Phase 3 readout est. (NCT07683000)
DESCRIPTION:Lenacapavir (Sunlenca)\, phase 3\, HIV.\nStudy: Study of Lenaca
 pavir\, Teropavimab\, and Zinlirvimab in Virologically Suppressed Adults W
 ith HIV-1 on Stable Oral Treatment Regimens\nEstimated primary completion:
  March 2029. This is a ClinicalTrials.gov estimate\, not a confirmed reado
 ut date\, and it can move.\nDrug page: https://assetmemo.bio/drug/lenacapa
 vir-sunlenca#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT07683000
URL:https://assetmemo.bio/drug/lenacapavir-sunlenca#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07806773-2785@assetmemo.bio
DTSTAMP:20261121T004512Z
DTSTART;VALUE=DATE:20290531
DTEND;VALUE=DATE:20290601
SUMMARY:TUB-040: Phase 2 readout est. (NCT07806773)
DESCRIPTION:TUB-040\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Study o
 f TUB-040 in Participants With Unresectable or Metastatic Nonsquamous Non-
 small Cell Lung Cancer\nEstimated primary completion: May 2029. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/tub-040#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT07806773
URL:https://assetmemo.bio/drug/tub-040#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06486441-1992@assetmemo.bio
DTSTAMP:20261121T004512Z
DTSTART;VALUE=DATE:20290630
DTEND;VALUE=DATE:20290701
SUMMARY:Sacituzumab Govitecan: Phase 3 readout est. (NCT06486441)
DESCRIPTION:Sacituzumab Govitecan\, phase 3\, Endometrial Cancer.\nStudy: S
 tudy of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Pa
 rticipants With Endometrial Cancer After Platinum-Based Chemotherapy and I
 mmunotherapy (ASCENT-GYN-01/GOG-3104/ENGOT-en26)\nEstimated primary comple
 tion: June 2029. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/saci
 tuzumab-govitecan#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT06486441
URL:https://assetmemo.bio/drug/sacituzumab-govitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07743541-2785@assetmemo.bio
DTSTAMP:20261121T004512Z
DTSTART;VALUE=DATE:20290930
DTEND;VALUE=DATE:20291001
SUMMARY:TUB-040: Phase 1/2 readout est. (NCT07743541)
DESCRIPTION:TUB-040\, phase 1/2.\nStudy: Study of TUB-040 in Patients With 
 Recurrent or Progressive Uterine Cancer After Chemotherapy and Immune Ther
 apy\nEstimated primary completion: September 2029. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/tub-040#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT07743541
URL:https://assetmemo.bio/drug/tub-040#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05633667-1992@assetmemo.bio
DTSTAMP:20261121T004512Z
DTSTART;VALUE=DATE:20290930
DTEND;VALUE=DATE:20291001
SUMMARY:Sacituzumab Govitecan: Phase 2 readout est. (NCT05633667)
DESCRIPTION:Sacituzumab Govitecan\, phase 2\, Non-Small Cell Lung Cancer.\n
 Study: Study of Novel Treatment Combinations in Patients With Lung Cancer\
 nEstimated primary completion: September 2029. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/sacituzumab-govitecan#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT05633667
URL:https://assetmemo.bio/drug/sacituzumab-govitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06801834-1992@assetmemo.bio
DTSTAMP:20261121T004512Z
DTSTART;VALUE=DATE:20291031
DTEND;VALUE=DATE:20291101
SUMMARY:Sacituzumab Govitecan: Phase 3 readout est. (NCT06801834)
DESCRIPTION:Sacituzumab Govitecan\, phase 3.\nStudy: Study of Sacituzumab G
 ovitecan Versus Standard of Care in Participants With Previously Treated E
 xtensive Stage Small Cell Lung Cancer\nEstimated primary completion: Octob
 er 2029. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/sacituzumab-
 govitecan#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT06801834
URL:https://assetmemo.bio/drug/sacituzumab-govitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03547973-1992@assetmemo.bio
DTSTAMP:20261121T004512Z
DTSTART;VALUE=DATE:20300430
DTEND;VALUE=DATE:20300501
SUMMARY:Sacituzumab Govitecan: Phase 2 readout est. (NCT03547973)
DESCRIPTION:Sacituzumab Govitecan\, phase 2\, Urothelial Carcinoma.\nStudy:
  Study of Sacituzumab Govitecan in Participants With Urothelial Cancer Tha
 t Cannot Be Removed or Has Spread\nEstimated primary completion: April 203
 0. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, 
 and it can move.\nDrug page: https://assetmemo.bio/drug/sacituzumab-govite
 can#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 03547973
URL:https://assetmemo.bio/drug/sacituzumab-govitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07910903-3157@assetmemo.bio
DTSTAMP:20261121T004512Z
DTSTART;VALUE=DATE:20300531
DTEND;VALUE=DATE:20300601
SUMMARY:Gamgertamig (CM336): Phase 3 readout est. (NCT07910903)
DESCRIPTION:Gamgertamig (CM336)\, phase 3\, Multiple Myeloma.\nStudy: Study
  of CM336+CM313 Combination Therapy in Patients With Relapsed or Refractor
 y Multiple Myeloma\nEstimated primary completion: May 2030. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/gamgertamig-cm336#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT07910903
URL:https://assetmemo.bio/drug/gamgertamig-cm336#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06532656-11020@assetmemo.bio
DTSTAMP:20261121T004512Z
DTSTART;VALUE=DATE:20300731
DTEND;VALUE=DATE:20300801
SUMMARY:Bictegravir/lenacapavir (Bixlenvo): Phase 2/3 readout est. (NCT0653
 2656)
DESCRIPTION:Bictegravir/lenacapavir (Bixlenvo)\, phase 2/3\, HIV.\nStudy: S
 tudy of Bictegravir/Lenacapavir in Children and Adolescents With HIV-1\nEs
 timated primary completion: July 2030. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/bictegravir-lenacapavir-bixlenvo#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT06532656
URL:https://assetmemo.bio/drug/bictegravir-lenacapavir-bixlenvo#upcoming-ev
 ents
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06051617-1117@assetmemo.bio
DTSTAMP:20261121T004512Z
DTSTART;VALUE=DATE:20300831
DTEND;VALUE=DATE:20300901
SUMMARY:Livdelzi (Seladelpar): Phase 3 readout est. (NCT06051617)
DESCRIPTION:Livdelzi (Seladelpar)\, phase 3\, Primary Biliary Cholangitis.\
 nStudy: Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and 
 Compensated Cirrhosis\nEstimated primary completion: August 2030. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/seladelpar#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT06051617
URL:https://assetmemo.bio/drug/seladelpar#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07708727-966@assetmemo.bio
DTSTAMP:20261121T004512Z
DTSTART;VALUE=DATE:20301031
DTEND;VALUE=DATE:20301101
SUMMARY:Lenacapavir (Sunlenca): Phase 2/3 readout est. (NCT07708727)
DESCRIPTION:Lenacapavir (Sunlenca)\, phase 2/3\, HIV.\nStudy: Study of an I
 njectable Regimen of GS-3242 With Lenacapavir Compared to Biktarvy in Peop
 le New to HIV-1 Treatment\nEstimated primary completion: October 2030. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/lenacapavir-sunlenca#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0770872
 7
URL:https://assetmemo.bio/drug/lenacapavir-sunlenca#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06608927-2695@assetmemo.bio
DTSTAMP:20261121T004512Z
DTSTART;VALUE=DATE:20301130
DTEND;VALUE=DATE:20301201
SUMMARY:Quemliclustat: Phase 3 readout est. (NCT06608927)
DESCRIPTION:Quemliclustat\, phase 3\, Pancreatic Ductal Adenocarcinoma.\nSt
 udy: Study of Quemliclustat and Chemotherapy Versus Placebo and Chemothera
 py in Patients With Metastatic Pancreatic Ductal Adenocarcinoma\nEstimated
  primary completion: 30 November 2030. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/quemliclustat#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT06608927
URL:https://assetmemo.bio/drug/quemliclustat#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07903506-3142@assetmemo.bio
DTSTAMP:20261121T004512Z
DTSTART;VALUE=DATE:20390331
DTEND;VALUE=DATE:20390401
SUMMARY:Anitocabtagene autoleucel: Phase 3 readout est. (NCT07903506)
DESCRIPTION:Anitocabtagene autoleucel\, phase 3\, Multiple Myeloma.\nStudy:
  To Evaluate Safety and Efficacy of Anitocabtagene Autoleucel Versus Autol
 ogous Stem Cell Transplant in Newly Diagnosed Multiple Myeloma\nEstimated 
 primary completion: March 2039. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/anitocabtagene-autoleucel#upcoming-events\nRegistry record: htt
 ps://clinicaltrials.gov/study/NCT07903506
URL:https://assetmemo.bio/drug/anitocabtagene-autoleucel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07887672-3142@assetmemo.bio
DTSTAMP:20261121T004512Z
DTSTART;VALUE=DATE:20420228
DTEND;VALUE=DATE:20420301
SUMMARY:Anitocabtagene autoleucel: Phase 3 readout est. (NCT07887672)
DESCRIPTION:Anitocabtagene autoleucel\, phase 3\, Multiple Myeloma.\nStudy:
  A Trial to Evaluate Safety and Efficacy of Anitocabtagene Autoleucel Vers
 us Standard of Care in Newly Diagnosed Multiple Myeloma\nEstimated primary
  completion: February 2042. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/anitocabtagene-autoleucel#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT07887672
URL:https://assetmemo.bio/drug/anitocabtagene-autoleucel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
